| 供应商 | 上海联迈生物工程有限公司 |
| 数量 | 大量 |
| 靶点 | 详见说明书 |
| 级别 | 1 |
| 目录编号 | LM-15576R-FITC |
| 克隆性 | 多克隆 |
| 抗原来源 | Rabbit |
| 保质期 | 1年 |
| 抗体英文名 | Anti-IGLK/FITC |
| 抗体名 | Anti-IGLK/FITC |
| 标记物 | FITC标记 |
| 宿主 | Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, |
| 适应物种 | Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, |
| 免疫原 | 详见说明书 |
| 亚型 | IGg |
| 形态 | 粉末、液体、冻干粉 |
| 应用范围 | IF=1:50-200 |
| 浓度 | 1mg/ml |
| 保存条件 | -20 °C |
| 规格 | 100ul |
| 英文名称 | Anti-IGLK/FITC |
| 中文名称 | FITC标记的IV型己糖激酶抗体 |
| 别 名 | ATP:D-hexose 6 phosphotransferase; FGQTL3; GCK; GK; GLK; Glucokinase; Hexokinase D; Hexokinase D, pancreatic isozyme; Hexokinase type IV; Hexokinase-4; Hexokinase-D; HHF3; HK IV; HK4; HXK4_HUMAN; HXKP; LGLK; MODY2. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 细胞生物 免疫学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 52kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human IGLK |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI). [provided by RefSeq, Apr 2009]. Function: Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when glucose is abundant. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. Subunit: Monomer. Tissue Specificity: Isoform 1 is expressed in pancreas. Isoform 2 and isoform 3 is expressed in liver. DISEASE: Maturity-onset diabetes of the young 2 (MODY2) [MIM:125851]: A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. Note=The disease is caused by mutations affecting the gene represented in this entry. Familial hyperinsulinemic hypoglycemia 3 (HHF3) [MIM:602485]: Most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the hexokinase family. Database links: Entrez Gene: 2645 Human Omim: 138079 Human SwissProt: P35557 Human Unigene: 1270 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
